CytoSorbents

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CytoSorbents reports growth in treatments and sales despite margin challenges

CytoSorbents demonstrated strong performance in treatment deliveries and sales momentum, despite margin challenges.
The company's focus on R&D and regulatory expertise positions it well for future growth opportunities.
Operational improvements and market expansion efforts are key to overcoming current challenges and driving profitability.
With a favorable competitive position and strategic initiatives, CytoSorbents aims to capitalize on emerging market opportunities.

CytoSorbents reports robust Q1 performance and eyes market expansion

CytoSorbents demonstrated strong performance in Q1 2023 with notable revenue and treatment milestones, alongside strategic market expansion efforts.
While facing challenges such as declining gross margins and managing costs, the company is focused on leveraging opportunities for growth and profitability.
Overall, CytoSorbents' financial health, product advancements, and market strategies position it well for future success and market expansion.

CytoSorbents reports robust Q2 earnings, eyes U.S. market expansion

CytoSorbents' Q2 2023 performance reflects strong revenue growth, operational milestones, and strategic partnerships driving future expansion.
While facing challenges in managing cash burn and regulatory hurdles, the company is well-positioned to capitalize on market opportunities.
With a focus on product innovation, market expansion, and financial sustainability, CytoSorbents aims to drive continued growth and market success.

CytoSorbents excels in Q3, eyes FDA approval and market expansion

CytoSorbents reported strong financial performance in Q3 2023, with revenue growth and a robust gross margin.
The company's focus on critical care markets and progress in the STAR-T trial indicate promising growth potential.
Challenges lie in maintaining cash reserves, securing FDA approvals, and navigating market competition.
Opportunities include expanding product portfolio, exploring capital sources, and leveraging favorable market conditions in Canada.

CytoSorb reports revenue growth and margin improvement in 2023

CytoSorb showed solid performance in 2023 with revenue growth and margin improvement.
Strategic partnerships and government support position the company for future growth.
Challenges include distributor order delays and market uncertainties in Germany.
Opportunities lie in new product initiatives, regulatory submissions, and international expansion.

CytoSorbents reports robust Q1 performance, eyes FDA submissions for growth

CytoSorbents delivered strong financial and operational performance in Q1 2024, driven by revenue growth and improved margins.
While facing challenges such as lower grant income and the need to maintain consistent performance, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, market expansion, and financial prudence, CytoSorbents aims to sustain its positive momentum throughout the year.

CytoSorbents reports revenue growth and operational improvements in Q2 2024

CytoSorbents' Q2 2024 showed positive revenue growth, operational improvements, and strategic advancements.
The company's focus on financial stability, regulatory progress, and cost efficiency bodes well for future performance.
While challenges like operational losses and regulatory hurdles persist, opportunities for growth and optimization are evident.
Overall, CytoSorbents is positioned for continued growth and success with a solid financial foundation and strategic direction.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.

MONMOUTH JUNCTION, N.J. and BOLOGNA, Italy, Aug. 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purification, announce the commercial launch of Aferetica's PerLife™ ex vivo organ perfusion system for kidney and liver transplant and CytoSorbents' PerSorb™ adsorber, based on the CytoSorbents ECOS-300CY™ sorbent technology to remove inflammatory mediators during ex vivo organ perfusion, at the European Society of Organ Transplantation (ESOT) Congress in Milan, Italy from August 29 – September 1, 2021.

CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress

The FDA has granted a second Breakthrough Device designation to  CytoSorbents Corporation's (NASDAQ: CTSO) DrugSorb-ATR Antithrombotic Removal System.  The designation covers removing the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of severe perioperative bleeding in cardiothoracic surgery.

CytoSorbents' Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag

MONMOUTH JUNCTION, N.J., Aug. 12, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that the Company has been granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the U.S. Food and Drug Administration (FDA).

Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery

CytoSorbents Corporation (NASDAQ: CTSO) reported Q2 revenue of $12 million, up 23% Y/Y, but missing the consensus of $12.27 million. Product sales increased 19% Y/Y to $11.4 million.

CytoSorbents Q2 Earnings Lag Consensus, Higher Costs Weigh On Bottom Line

CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q2 2021 Results - Earnings Call Transcript

MONMOUTH JUNCTION, N.J., Aug. 3, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, reports financial and operating results for the quarter and six months ending June 30, 2021.

CytoSorbents Reports Second Quarter 2021 Financial and Operational Results

MONMOUTH JUNCTION, N.J., July 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the successful completion of its MISSION 100,000 international fundraising campaign to fight the spread of COVID-19, raising $100,000 to benefit the global, not-for-profit humanitarian organization, CARE.

CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Global Humanitarian Organization, CARE

MONMOUTH JUNCTION, N.J., July 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, will report second quarter 2021 operating and financial results after the market close on August 3, 2021.

CytoSorbents to Report Second Quarter 2021 Operating and Financial Results

The biotech company took another step toward introducing a new way of performing bypass surgeries.

Here's Why Cytosorbents Is Up 17% Today

CytoSorbents Corporation (NASDAQ: CTSO) receives full FDA approval to conduct the STAR-T trial in the U.S. to support regulatory clearance of DrugSorb Antithrombotic Removal (ATR) system for intraoperative ticagrelor removal during cardiothoracic surgery. This study is being performed under the previously announced FDA Breakthrough Designation received in April 2020.

CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery

MONMOUTH JUNCTION, N.J., July 6, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) announces the full approval of its Investigational Device Exemption (IDE) application to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor) double-blind, randomized, controlled trial (RCT) in the United States to support FDA regulatory clearance.

CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery

MONMOUTH JUNCTION, N.J., June 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces the appointment of Terri Anne Powers, MBA, IRC, as Vice President of Investor Relations and Corporate Communications effective today.

CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications

MONMOUTH JUNCTION, N.J., May 27, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Company's progress and outlook at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021.

CytoSorbents to Present at the Jefferies Virtual Healthcare Conference

MONMOUTH JUNCTION, N.J., May 25, 2021 /PRNewswire/ -- CytoSorbents Corporation  (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in the intensive care unit (ICU) and cardiac surgery, announces that the Singapore Health Sciences Authority (HSA) has now approved registration of CytoSorb® for all equivalent European Union (E.U.

CytoSorb® Registered and Commercially Available in Singapore

MONMOUTH JUNCTION, N.J., May 19, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Company's progress and outlook at the UBS Global Healthcare Virtual Conference and provide a prerecorded presentation at the Oppenheimer MedTech, Tools and Diagnostic Summit on Wednesday, May 26, 2021.

CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit

The U.S Army Medical Research and Development Command has awarded CytoSorbents Corporation (NASDAQ: CTSO), a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR) contract of $1.5 million over 28 months. The funding will be used to advance the development of the K+ontrol platform to treat severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine.

CytoSorbents, Progenity Receive Funding For Product Development

MONMOUTH JUNCTION, N.J., May 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® and other blood purification technologies to treat deadly conditions in critically-ill and cardiac surgery patients around the world, announced the U.S Army Medical Research and Development Command has awarded CytoSorbents a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR) contract, valued at $1,499,987 over 28 months, to advance development of the K+ontrol™ platform for the treatment of severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine.

CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury

CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q1 2021 Results - Earnings Call Transcript

MONMOUTH JUNCTION, N.J., May 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader using its CytoSorb® blood purification technology to treat life-threatening conditions in critically-ill and cardiac surgery patients around the world, reports financial and operating results for the quarter ended March 31, 2021.

CytoSorbents Reports First Quarter 2021 Financial and Operational Results

MONMOUTH JUNCTION, N.J., April 27, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2021 financial results after the market close on Tuesday, May 4, 2021 at 4:45PM EST.

CytoSorbents to Report Q1 2021 Operating and Financial Results

The FDA has signed off conditional approval for the STAR-T study to assess CytoSorbents Corporation's (NASDAQ: CTSO) blood purification device, CytoSorb, to remove Ticagrelor. The company can now initiate clinical trial agreement negotiations and institutional review board submissions.

CytoSorbents To Start US Study With CytoSorb For Ticagrelor Removal

MONMOUTH JUNCTION, N.J., April 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader whose flagship E.U.

U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery

MONMOUTH JUNCTION, N.J., March 29, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb ® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the lease of its new global headquarters in Princeton, NJ.

CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey

MONMOUTH JUNCTION, N.J., March 16, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) announces the filing of an Investigational Device Exemption (IDE) application to conduct the clinical study, "Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)," in the United States to support an initial FDA regulatory approval.

CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery

MONMOUTH JUNCTION, N.J., March 12, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Oppenheimer 31st Annual Healthcare Conference.

News for CytoSorbents Stock (CTSO)